Ensysce Publishes Clinical Study on MPAR Overdose Protection Technology

Ensysce Biosciences announced the publication of the first clinical manuscript describing its MPAR overdose protection technology. The paper, titled "Formulation and a Phase 1 Clinical Study of PF614-MPAR, an Oxycodone Prodrug with Oral Opioid Overdose Protection," appears online in the Journal of Opioid Management Jan/Feb 2026 issue. PF614-MPAR is the first opioid candidate specifically designed to provide active protection against oral overdose-a limitation not addressed by currently marketed abuse-deterrent formulations. MPAR technology is engineered to maintain therapeutic opioid exposure when taken as prescribed while automatically limiting additional opioid release when excessive numbers of pills are consumed. Data presented in the publication demonstrate that PF614-MPAR achieved appropriate opioid plasma levels under normal dosing conditions, while preventing large increases in opioid delivery when supratherapeutic doses were administered. These findings support the potential for a fundamentally new safety paradigm in opioid analgesia. MPAR previously received Breakthrough Therapy Designation from the U.S. Food and Drug Administration in January 2024 based on this clinical evidence and the technology is protected by a growing intellectual property portfolio extending through 2042. "This peer-reviewed publication marks a defining milestone not only for Ensysce, but for the field of pain medicine," said Dr. Lynn Kirkpatrick, CEO. "CDC data projects that almost 80,000 people die every year from opioid overdose of which prescription opioids factor into 12.4% of these deaths. These numbers, which amount to 30 deaths per day, are still considered a major health crisis. Importantly, to combat against overdose, MPAR introduces a new class of chemically programmed opioids designed to protect patients even when dosing errors or misuse occur."